Dr Sammons on the SONIA Trial of First-Line CDK4/6 Inhibitor

Sarah Sammons, MD, discusses whether CDK4/6 inhibitors should be considered a standard first line treatment within hormone receptor–positive, HER2-negative advanced breast cancer according to primary results from the phase 3 SONIA trial.

Related Keywords

Sarah Sammons , Dana Farber Cancer Institute , Metastatic Breast Cancer Program , Estrogen Receptor Positive , Er2 Negative Advanced Or Metastatic Breast Cancer , Cdk4 6 Inhibitors , Phase 3 Sonia Trial , Hormone Receptor Hr Positive , Er2 Negative Advanced Breast Cancer ,